United Therapeutics (NASDAQ:UTHR) had its price objective boosted by JPMorgan Chase & Co. from $118.00 to $126.00 in a research report sent to investors on Friday morning. The brokerage currently has a neutral rating on the biotechnology company’s stock.
Several other analysts also recently commented on the stock. Wedbush raised their price objective on shares of United Therapeutics from $234.00 to $253.00 and gave the stock an outperform rating in a research report on Thursday, August 2nd. TheStreet downgraded shares of United Therapeutics from a b rating to a c+ rating in a research report on Thursday, September 6th. BidaskClub downgraded shares of United Therapeutics from a buy rating to a hold rating in a research report on Monday, September 24th. Standpoint Research raised shares of United Therapeutics from a hold rating to a buy rating in a research report on Friday, October 12th. Finally, Zacks Investment Research downgraded shares of United Therapeutics from a strong-buy rating to a hold rating in a research report on Monday, October 22nd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. The company presently has a consensus rating of Hold and a consensus target price of $136.25.
NASDAQ:UTHR traded down $0.40 on Friday, reaching $114.64. 388,172 shares of the stock traded hands, compared to its average volume of 374,816. The company has a market capitalization of $5.00 billion, a PE ratio of 8.17, a P/E/G ratio of 25.87 and a beta of 1.23. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.35 and a current ratio of 4.32. United Therapeutics has a 1-year low of $100.57 and a 1-year high of $152.55.
United Therapeutics (NASDAQ:UTHR) last released its earnings results on Wednesday, October 31st. The biotechnology company reported $2.42 earnings per share for the quarter, missing analysts’ consensus estimates of $3.23 by ($0.81). The firm had revenue of $412.70 million for the quarter, compared to analyst estimates of $378.22 million. United Therapeutics had a net margin of 31.73% and a return on equity of 25.24%. The business’s revenue for the quarter was down 7.4% compared to the same quarter last year. During the same period in the prior year, the company posted $4.69 EPS. Research analysts predict that United Therapeutics will post 14.77 EPS for the current year.
In related news, Director Richard Giltner sold 3,240 shares of United Therapeutics stock in a transaction on Thursday, August 16th. The shares were sold at an average price of $129.38, for a total value of $419,191.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Christopher Causey sold 810 shares of United Therapeutics stock in a transaction on Thursday, September 6th. The shares were sold at an average price of $118.00, for a total transaction of $95,580.00. Following the completion of the sale, the director now directly owns 3,925 shares of the company’s stock, valued at approximately $463,150. The disclosure for this sale can be found here. In the last three months, insiders sold 4,860 shares of company stock valued at $611,161. 8.20% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of UTHR. Legal & General Group Plc grew its position in United Therapeutics by 7.8% in the 1st quarter. Legal & General Group Plc now owns 98,898 shares of the biotechnology company’s stock valued at $11,112,000 after purchasing an additional 7,156 shares during the period. Principal Financial Group Inc. grew its position in United Therapeutics by 2.8% in the 1st quarter. Principal Financial Group Inc. now owns 196,233 shares of the biotechnology company’s stock valued at $22,049,000 after purchasing an additional 5,396 shares during the period. Clinton Group Inc. acquired a new stake in United Therapeutics in the 2nd quarter valued at $815,000. State of Alaska Department of Revenue grew its position in United Therapeutics by 40.1% in the 2nd quarter. State of Alaska Department of Revenue now owns 4,720 shares of the biotechnology company’s stock valued at $534,000 after purchasing an additional 1,350 shares during the period. Finally, Fjarde AP Fonden Fourth Swedish National Pension Fund grew its position in United Therapeutics by 10.6% in the 2nd quarter. Fjarde AP Fonden Fourth Swedish National Pension Fund now owns 14,941 shares of the biotechnology company’s stock valued at $1,691,000 after purchasing an additional 1,437 shares during the period. 94.62% of the stock is owned by institutional investors and hedge funds.
About United Therapeutics
United Therapeutics Corporation, a biotechnology company, develops and commercializes products to address the unmet medical needs of patients with chronic and life-threatening diseases worldwide. The company's commercial products include Remodulin, a continuously-infused formulation of the prostacyclin analogue treprostinil for subcutaneous and intravenous administration to diminish symptoms associated with exercise in pulmonary arterial hypertension (PAH) patients; Tyvaso, an inhaled formulation of treprostinil to enhace the exercise ability in PAH patients; Orenitram, a tablet dosage form of treprostinil to enhance the exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.
Read More: Moving Average (MA)
Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.